{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:11:39Z","timestamp":1792192299275,"version":"4.4.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41585-020-0359-z","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:02:49Z","timestamp":1597748569000},"page":"555-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Understanding genomics and the immune environment of penile cancer to improve therapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6047-8431","authenticated-orcid":false,"given":"Ahmet Murat","family":"Aydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-312X","authenticated-orcid":false,"given":"Jacob J.","family":"Adashek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounsif","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Magliocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":false,"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"359_CR1","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ijc.31194","volume":"142","author":"BT Hansen","year":"2018","unstructured":"Hansen, B. T., Orumaa, M., Lie, A. K., Brennhovd, B. & Nygard, M. Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956\u20132015. Int. J. Cancer 142, 1586\u20131593 (2018).","journal-title":"Int. J. Cancer"},{"key":"359_CR2","doi-asserted-by":"crossref","first-page":"674.e1","DOI":"10.1016\/j.urolonc.2017.08.009","volume":"35","author":"MN Pham","year":"2017","unstructured":"Pham, M. N. et al. Contemporary survival trends in penile cancer: results from the National Cancer Database. Urol. Oncol. 35, 674.e1\u2013674.e9 (2017).","journal-title":"Urol. Oncol."},{"key":"359_CR3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s10552-013-0293-y","volume":"24","author":"M Arya","year":"2013","unstructured":"Arya, M. et al. Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control 24, 2169\u20132176 (2013).","journal-title":"Cancer Causes Control"},{"key":"359_CR4","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.urology.2010.04.008","volume":"76","author":"V Ficarra","year":"2010","unstructured":"Ficarra, V., Akduman, B., Bouchot, O., Palou, J. & Tobias-Machado, M. Prognostic factors in penile cancer. Urology 76, S66\u2013S73 (2010).","journal-title":"Urology"},{"key":"359_CR5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.urology.2014.11.048","volume":"85","author":"R Veeratterapillay","year":"2015","unstructured":"Veeratterapillay, R., Teo, L., Asterling, S. & Greene, D. Oncologic outcomes of penile cancer treatment at a UK supraregional center. Urology 85, 1097\u20131103 (2015).","journal-title":"Urology"},{"key":"359_CR6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1464-410X.2001.00379.x","volume":"88","author":"S Horenblas","year":"2001","unstructured":"Horenblas, S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int. 88, 473\u2013483 (2001).","journal-title":"BJU Int."},{"key":"359_CR7","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro, L. C. et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J. Clin. Oncol. 28, 3851\u20133857 (2010).","journal-title":"J. Clin. Oncol."},{"key":"359_CR8","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","volume":"109","author":"S Nicholson","year":"2013","unstructured":"Nicholson, S. et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001). Br. J. Cancer 109, 2554\u20132559 (2013).","journal-title":"Br. J. Cancer"},{"key":"359_CR9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0022-5347(05)68815-5","volume":"161","author":"GP Haas","year":"1999","unstructured":"Haas, G. P. et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J. Urol. 161, 1823\u20131825 (1999).","journal-title":"J. Urol."},{"key":"359_CR10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","volume":"113","author":"BC Carthon","year":"2014","unstructured":"Carthon, B. C., Ng, C. S., Pettaway, C. A. & Pagliaro, L. C. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 113, 871\u2013877 (2014).","journal-title":"BJU Int."},{"key":"359_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","volume":"14","author":"A Necchi","year":"2016","unstructured":"Necchi, A. et al. Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed. Clin. Genitourin. Cancer 14, 231\u2013236 (2016).","journal-title":"Clin. Genitourin. Cancer"},{"key":"359_CR12","first-page":"646","volume":"115","author":"OW Hakenberg","year":"2018","unstructured":"Hakenberg, O. W. et al. The diagnosis and treatment of penile cancer. Dtsch. Arztebl. Int. 115, 646\u2013652 (2018).","journal-title":"Dtsch. Arztebl. Int."},{"key":"359_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clgc.2014.06.005","volume":"13","author":"RS Djajadiningrat","year":"2015","unstructured":"Djajadiningrat, R. S., Bergman, A. M., van Werkhoven, E., Vegt, E. & Horenblas, S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin. Genitourin. Cancer 13, 44\u201349 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"359_CR14","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02305654 (2019)."},{"key":"359_CR15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","volume":"5","author":"DJ Canter","year":"2019","unstructured":"Canter, D. J. et al. The International Penile Advanced Cancer Trial (InPACT): rationale and current status. Eur. Urol. Focus. 5, 706\u2013709 (2019).","journal-title":"Eur. Urol. Focus."},{"key":"359_CR16","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.23743","volume":"113","author":"BY Hernandez","year":"2008","unstructured":"Hernandez, B. Y. et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998\u20132003. Cancer 113, 2883\u20132891 (2008).","journal-title":"Cancer"},{"key":"359_CR17","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2018.36.15_suppl.4514","volume":"36","author":"LM Pickering","year":"2018","unstructured":"Pickering, L. M. et al. VinCaP: a phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK\/12\/021). J. Clin. Oncol. 36, 4514\u20134514 (2018).","journal-title":"J. Clin. Oncol."},{"key":"359_CR18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 121, 348\u2013356 (2018).","journal-title":"BJU Int."},{"key":"359_CR19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2013.0075","volume":"11","author":"PE Clark","year":"2013","unstructured":"Clark, P. E. et al. Penile cancer: clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 11, 594\u2013615 (2013).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"359_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/CS20180436","volume":"133","author":"RH Horton","year":"2019","unstructured":"Horton, R. H. & Lucassen, A. M. Recent developments in genetic\/genomic medicine. Clin. Sci. 133, 697\u2013708 (2019).","journal-title":"Clin. Sci."},{"key":"359_CR21","first-page":"267","volume":"21","author":"DS Subramaniam","year":"2016","unstructured":"Subramaniam, D. S., Liu, S. V. & Giaccone, G. Novel approaches in cancer immunotherapy. Discov. Med. 21, 267\u2013274 (2016).","journal-title":"Discov. Med."},{"key":"359_CR22","first-page":"6940546","volume":"2017","author":"FS Hsu","year":"2017","unstructured":"Hsu, F. S., Su, C. H. & Huang, K. H. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J. Immunol. Res. 2017, 6940546 (2017).","journal-title":"J. Immunol. Res."},{"key":"359_CR23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.immuni.2018.06.003","volume":"48","author":"BA Helmink","year":"2018","unstructured":"Helmink, B. A., Gaudreau, P. O. & Wargo, J. A. Immune checkpoint blockade across the cancer care continuum. Immunity 48, 1077\u20131080 (2018).","journal-title":"Immunity"},{"key":"359_CR24","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"359_CR25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V. & Wargo, J. A. The microbiome, cancer, and cancer therapy. Nat. Med. 25, 377\u2013388 (2019).","journal-title":"Nat. Med."},{"key":"359_CR26","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084\u20131089 (2015).","journal-title":"Science"},{"key":"359_CR27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971\u2013976 (2013).","journal-title":"Science"},{"key":"359_CR28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10552-008-9276-9","volume":"20","author":"DM Backes","year":"2009","unstructured":"Backes, D. M., Kurman, R. J., Pimenta, J. M. & Smith, J. S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 20, 449\u2013457 (2009).","journal-title":"Cancer Causes Control"},{"key":"359_CR29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.21037\/tau.2017.05.19","volume":"6","author":"A Douglawi","year":"2017","unstructured":"Douglawi, A. & Masterson, T. A. Updates on the epidemiology and risk factors for penile cancer. Transl. Androl. Urol. 6, 785\u2013790 (2017).","journal-title":"Transl. Androl. Urol."},{"key":"359_CR30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719\u2013724 (2009).","journal-title":"Nature"},{"key":"359_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/gcc.1117","volume":"31","author":"G Alves","year":"2001","unstructured":"Alves, G. et al. Genetic imbalances in 26 cases of penile squamous cell carcinoma. Genes Chromosomes Cancer 31, 48\u201353 (2001).","journal-title":"Genes Chromosomes Cancer"},{"key":"359_CR32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/modpathol.3800931","volume":"20","author":"M Poetsch","year":"2007","unstructured":"Poetsch, M., Schuart, B. J., Schwesinger, G., Kleist, B. & Protzel, C. Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Mod. Pathol. 20, 1069\u20131077 (2007).","journal-title":"Mod. Pathol."},{"key":"359_CR33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/1940-6207.CAPR-14-0284","volume":"8","author":"AF Busso-Lopes","year":"2015","unstructured":"Busso-Lopes, A. F. et al. Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev. Res. 8, 149\u2013156 (2015).","journal-title":"Cancer Prev. Res."},{"key":"359_CR34","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-15-3134","volume":"76","author":"A Feber","year":"2016","unstructured":"Feber, A. et al. CSN1 somatic mutations in penile squamous cell carcinoma. Cancer Res. 76, 4720\u20134727 (2016).","journal-title":"Cancer Res."},{"key":"359_CR35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-61779-507-7_15","volume":"838","author":"S Ceulemans","year":"2012","unstructured":"Ceulemans, S., van der Ven, K. & Del-Favero, J. Targeted screening and validation of copy number variations. Methods Mol. Biol. 838, 311\u2013328 (2012).","journal-title":"Methods Mol. Biol."},{"key":"359_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physiolgenomics.00082.2012","volume":"45","author":"W Li","year":"2013","unstructured":"Li, W. & Olivier, M. Current analysis platforms and methods for detecting copy number variation. Physiol. Genomics 45, 1\u201316 (2013).","journal-title":"Physiol. Genomics"},{"key":"359_CR37","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","volume":"75","author":"AS McDaniel","year":"2015","unstructured":"McDaniel, A. S. et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 75, 5219\u20135227 (2015).","journal-title":"Cancer Res."},{"key":"359_CR38","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-17-0972","volume":"23","author":"G Seed","year":"2017","unstructured":"Seed, G. et al. Gene copy number estimation from targeted next-generation sequencing of prostate cancer biopsies: analytic validation and clinical qualification. Clin. Cancer Res. 23, 6070\u20136077 (2017).","journal-title":"Clin. Cancer Res."},{"key":"359_CR39","doi-asserted-by":"publisher","DOI":"10.7554\/eLife,37294","author":"H Hieronymus","year":"2018","unstructured":"Hieronymus, H. et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. eLife 7, e37294 (2018).","journal-title":"eLife"},{"key":"359_CR40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","volume":"201","author":"JM Jacob","year":"2019","unstructured":"Jacob, J. M. et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J. Urol. 201, 541\u2013548 (2019).","journal-title":"J. Urol."},{"key":"359_CR41","volume":"11","author":"L Tang","year":"2016","unstructured":"Tang, L. & Wang, K. Chronic inflammation in skin malignancies. J. Mol. Signal. 11, 2 (2016).","journal-title":"J. Mol. Signal."},{"key":"359_CR42","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/ijc.30621","volume":"140","author":"P Halonen","year":"2017","unstructured":"Halonen, P. et al. Lichen sclerosus and risk of cancer. Int. J. Cancer 140, 1998\u20132002 (2017).","journal-title":"Int. J. Cancer"},{"key":"359_CR43","doi-asserted-by":"crossref","first-page":"575242","DOI":"10.1155\/2012\/575242","volume":"2012","author":"M Tezal","year":"2012","unstructured":"Tezal, M. Interaction between chronic inflammation and oral HPV infection in the etiology of head and neck cancers. Int. J. Otolaryngol. 2012, 575242 (2012).","journal-title":"Int. J. Otolaryngol."},{"key":"359_CR44","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(98)08228-2","volume":"353","author":"JJ Powell","year":"1999","unstructured":"Powell, J. J. & Wojnarowska, F. Lichen sclerosus. Lancet 353, 1777\u20131783 (1999).","journal-title":"Lancet"},{"key":"359_CR45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1464-410X.2012.11773.x","volume":"111","author":"P Philippou","year":"2013","unstructured":"Philippou, P. et al. Genital lichen sclerosus\/balanitis xerotica obliterans in men with penile carcinoma: a critical analysis. BJU Int. 111, 970\u2013976 (2013).","journal-title":"BJU Int."},{"key":"359_CR46","first-page":"197","volume":"21","author":"D Bazalinski","year":"2017","unstructured":"Bazalinski, D., Przybek-Mita, J., Baranska, B. & Wiech, P. Marjolin\u2019s ulcer in chronic wounds \u2014 review of available literature. Contemp. Oncol. 21, 197\u2013202 (2017).","journal-title":"Contemp. Oncol."},{"key":"359_CR47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.15324","volume":"177","author":"AC Green","year":"2017","unstructured":"Green, A. C. & Olsen, C. M. Cutaneous squamous cell carcinoma: an epidemiological review. Br. J. Dermatol. 177, 373\u2013381 (2017).","journal-title":"Br. J. Dermatol."},{"key":"359_CR48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101605","volume":"17","author":"T Eitsuka","year":"2016","unstructured":"Eitsuka, T., Tatewaki, N., Nishida, H., Nakagawa, K. & Miyazawa, T. Synergistic anticancer effect of tocotrienol combined with chemotherapeutic agents or dietary components: a review. Int. J. Mol. Sci. 17, 1605 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"359_CR49","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt, M. J. & Moasser, M. M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci. 65, 1566\u20131584 (2008).","journal-title":"Cell Mol. Life Sci."},{"key":"359_CR50","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","volume":"12","author":"M Scaltriti","year":"2006","unstructured":"Scaltriti, M. & Baselga, J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12, 5268\u20135272 (2006).","journal-title":"Clin. Cancer Res."},{"key":"359_CR51","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.2147\/OTT.S198945","volume":"12","author":"S Wang","year":"2019","unstructured":"Wang, S. & Li, J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther. 12, 6535\u20136548 (2019).","journal-title":"Onco Targets Ther."},{"key":"359_CR52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13\u201321 (2015).","journal-title":"Ann. Oncol."},{"key":"359_CR53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","volume":"21","author":"SM Ali","year":"2016","unstructured":"Ali, S. M. et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncologist 21, 33\u201339 (2016).","journal-title":"Oncologist"},{"key":"359_CR54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten, T. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259\u2013267 (2016).","journal-title":"Clin. Cancer Res."},{"key":"359_CR55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2019.00179","volume":"9","author":"C Fumarola","year":"2019","unstructured":"Fumarola, C. et al. Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front. Oncol. 9, 179 (2019).","journal-title":"Front. Oncol."},{"key":"359_CR56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","volume":"115","author":"GE Konecny","year":"2016","unstructured":"Konecny, G. E. & Kristeleit, R. S. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions. Br. J. Cancer 115, 1157\u20131173 (2016).","journal-title":"Br. J. Cancer"},{"key":"359_CR57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40164-019-0154-9","volume":"8","author":"M Yi","year":"2019","unstructured":"Yi, M. et al. Advances and perspectives of PARP inhibitors. Exp. Hematol. Oncol. 8, 29 (2019).","journal-title":"Exp. Hematol. Oncol."},{"key":"359_CR58","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin, M. H. & Oh, D. Y. ATM in DNA repair in cancer. Pharmacol. Ther. 203, 107391 (2019).","journal-title":"Pharmacol. Ther."},{"key":"359_CR59","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.1706392114","volume":"114","author":"CC Chen","year":"2017","unstructured":"Chen, C. C. et al. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc. Natl Acad. Sci. USA 114, 7665\u20137670 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"359_CR60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","volume":"104","author":"K Cichowski","year":"2001","unstructured":"Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593\u2013604 (2001).","journal-title":"Cell"},{"key":"359_CR61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1101\/gad.862101","volume":"15","author":"Y Zhu","year":"2001","unstructured":"Zhu, Y. et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15, 859\u2013876 (2001).","journal-title":"Genes Dev."},{"key":"359_CR62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","volume":"2","author":"E Castellano","year":"2011","unstructured":"Castellano, E. & Downward, J. RAS interaction with PI3K: more than just another effector pathway. Genes. Cancer 2, 261\u2013274 (2011).","journal-title":"Genes. Cancer"},{"key":"359_CR63","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"YS Yap","year":"2014","unstructured":"Yap, Y. S. et al. The NF1 gene revisited \u2014 from bench to bedside. Oncotarget 5, 5873\u20135892 (2014).","journal-title":"Oncotarget"},{"key":"359_CR64","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"359_CR65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","volume":"18","author":"AM Grimaldi","year":"2017","unstructured":"Grimaldi, A. M. et al. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am. J. Clin. Dermatol. 18, 745\u2013754 (2017).","journal-title":"Am. J. Clin. Dermatol."},{"key":"359_CR66","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1101\/gad.1308805","volume":"19","author":"K Hamada","year":"2005","unstructured":"Hamada, K. et al. The PTEN\/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 19, 2054\u20132065 (2005).","journal-title":"Genes Dev."},{"key":"359_CR67","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","volume":"20","author":"T Tian","year":"2019","unstructured":"Tian, T., Li, X. & Zhang, J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int. J. Mol. Sci. 20, 755 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"359_CR68","doi-asserted-by":"crossref","first-page":"42393","DOI":"10.18632\/oncotarget.9877","volume":"7","author":"CS Matsumoto","year":"2016","unstructured":"Matsumoto, C. S. et al. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget 7, 42393\u201342407 (2016).","journal-title":"Oncotarget"},{"key":"359_CR69","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1517\/13543784.2012.726218","volume":"21","author":"M Chavez-MacGregor","year":"2012","unstructured":"Chavez-MacGregor, M. & Gonzalez-Angulo, A. M. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin. Investig. Drugs 21, 1835\u20131843 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"359_CR70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/187152010793498663","volume":"10","author":"H Zhou","year":"2010","unstructured":"Zhou, H., Luo, Y. & Huang, S. Updates of mTOR inhibitors. Anticancer Agents Med. Chem. 10, 571\u2013581 (2010).","journal-title":"Anticancer Agents Med. Chem."},{"key":"359_CR71","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"359_CR72","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","volume":"103","author":"AG Bader","year":"2006","unstructured":"Bader, A. G., Kang, S. & Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA 103, 1475\u20131479 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"359_CR73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162586","volume":"11","author":"MA Budzinska","year":"2016","unstructured":"Budzinska, M. A. et al. Accumulation of deleterious passenger mutations is associated with the progression of hepatocellular carcinoma. PLoS ONE 11, e0162586 (2016).","journal-title":"PLoS ONE"},{"key":"359_CR74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1086\/513473","volume":"80","author":"GV Kryukov","year":"2007","unstructured":"Kryukov, G. V., Pennacchio, L. A. & Sunyaev, S. R. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am. J. Hum. Genet. 80, 727\u2013739 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"359_CR75","volume":"7","author":"FA Marchi","year":"2017","unstructured":"Marchi, F. A. et al. Multidimensional integrative analysis uncovers driver candidates and biomarkers in penile carcinoma. Sci. Rep. 7, 6707 (2017).","journal-title":"Sci. Rep."},{"key":"359_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.257","volume":"7","author":"Y Voges","year":"2016","unstructured":"Voges, Y. et al. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell Death Dis. 7, e2410 (2016).","journal-title":"Cell Death Dis."},{"key":"359_CR77","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13046-019-1362-1","volume":"38","author":"F Li","year":"2019","unstructured":"Li, F., Aljahdali, I. & Ling, X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J. Exp. Clin. Cancer Res. 38, 368 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"359_CR78","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/JTO.0000000000000285","volume":"9","author":"R Natale","year":"2014","unstructured":"Natale, R. et al. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J. Thorac. Oncol. 9, 1704\u20131708 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"359_CR79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-014-3238-6","volume":"149","author":"MR Clemens","year":"2015","unstructured":"Clemens, M. R. et al. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat. 149, 171\u2013179 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"359_CR80","first-page":"399","volume":"8","author":"D Li","year":"2018","unstructured":"Li, D., Hu, C. & Li, H. Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed. Rep. 8, 399\u2013406 (2018).","journal-title":"Biomed. Rep."},{"key":"359_CR81","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","volume":"17","author":"K Yamanaka","year":"2011","unstructured":"Yamanaka, K. et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 17, 5423\u20135431 (2011).","journal-title":"Clin. Cancer Res."},{"key":"359_CR82","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.18632\/aging.101085","volume":"8","author":"D Decaudin","year":"2016","unstructured":"Decaudin, D. & Le Tourneau, C. Combinations of targeted therapies in human cancers. Aging 8, 2258\u20132259 (2016).","journal-title":"Aging"},{"key":"359_CR83","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","volume":"32","author":"DB Johnson","year":"2014","unstructured":"Johnson, D. B. et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol. 32, 3697\u20133704 (2014).","journal-title":"J. Clin. Oncol."},{"key":"359_CR84","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell, K. L. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585\u20132592 (2012).","journal-title":"J. Clin. Oncol."},{"key":"359_CR85","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.30435","volume":"123","author":"SY Lim","year":"2017","unstructured":"Lim, S. Y., Menzies, A. M. & Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 123, 2118\u20132129 (2017).","journal-title":"Cancer"},{"key":"359_CR86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen, T. B. et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 20, 145\u2013158 (2019).","journal-title":"Lancet Oncol."},{"key":"359_CR87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaad.2012.12.973","volume":"69","author":"S Mannweiler","year":"2013","unstructured":"Mannweiler, S., Sygulla, S., Winter, E. & Regauer, S. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J. Am. Acad. Dermatol. 69, 73\u201381 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"359_CR88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0959-437X(99)80004-5","volume":"9","author":"NE Sharpless","year":"1999","unstructured":"Sharpless, N. E. & DePinho, R. A. The INK4A\/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22\u201330 (1999).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"359_CR89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","volume":"2","author":"N Rivlin","year":"2011","unstructured":"Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466\u2013474 (2011).","journal-title":"Genes Cancer"},{"key":"359_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1711720103","volume":"172","author":"PA Hall","year":"1994","unstructured":"Hall, P. A. & Lane, D. P. p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J. Pathol. 172, 1\u20134 (1994).","journal-title":"J. Pathol."},{"key":"359_CR91","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.humpath.2011.06.013","volume":"43","author":"RM Rocha","year":"2012","unstructured":"Rocha, R. M. et al. A clinical, pathologic, and molecular study of p53 and murine double minute 2 in penile carcinogenesis and its relation to prognosis. Hum. Pathol. 43, 481\u2013488 (2012).","journal-title":"Hum. Pathol."},{"key":"359_CR92","first-page":"8345893","volume":"2018","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Prognostic significance of p16INK4a expression in penile squamous cell carcinoma: a meta-analysis with trial sequential analysis. Biomed. Res. Int. 2018, 8345893 (2018).","journal-title":"Biomed. Res. Int."},{"key":"359_CR93","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16918-w","volume":"7","author":"AE Albers","year":"2017","unstructured":"Albers, A. E., Qian, X., Kaufmann, A. M. & Coordes, A. Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci. Rep. 7, 16715 (2017).","journal-title":"Sci. Rep."},{"key":"359_CR94","volume":"9","author":"J Lin","year":"2014","unstructured":"Lin, J., Albers, A. E., Qin, J. & Kaufmann, A. M. Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis. PLoS ONE 9, e106384 (2014).","journal-title":"PLoS ONE"},{"key":"359_CR95","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.18632\/oncotarget.23545","volume":"9","author":"G Sun","year":"2018","unstructured":"Sun, G. et al. The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget 9, 8081\u20138088 (2018).","journal-title":"Oncotarget"},{"key":"359_CR96","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1055-9965.EPI-18-0322","volume":"27","author":"FL Sand","year":"2018","unstructured":"Sand, F. L., Rasmussen, C. L., Frederiksen, M. H., Andersen, K. K. & Kjaer, S. K. Prognostic significance of HPV and p16 status in men diagnosed with penile cancer: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 27, 1123\u20131132 (2018).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"359_CR97","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbcan.2017.01.003","volume":"1867","author":"A Davis","year":"2017","unstructured":"Davis, A., Gao, R. & Navin, N. Tumor evolution: linear, branching, neutral or punctuated? Biochim. Biophys. Acta Rev. Cancer 1867, 151\u2013161 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"359_CR98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2019.37.7_suppl.505","volume":"37","author":"J Chahoud","year":"2019","unstructured":"Chahoud, J. et al. Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors. J. Clin. Oncol. 37, 505\u2013505 (2019).","journal-title":"J. Clin. Oncol."},{"key":"359_CR99","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2019.37.7_suppl.514","volume":"37","author":"J Jacob","year":"2019","unstructured":"Jacob, J. et al. Penile and uterine cervical squamous cell carcinomas: a comparative genomic profiling study. J. Clin. Oncol. 37, 514\u2013514 (2019).","journal-title":"J. Clin. Oncol."},{"key":"359_CR100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41585-018-0040-y","volume":"15","author":"J Tward","year":"2018","unstructured":"Tward, J. The case for nonsurgical therapy of nonmetastatic penile cancer. Nat. Rev. Urol. 15, 574\u2013584 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"359_CR101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017517","volume":"6","author":"E Stankiewicz","year":"2011","unstructured":"Stankiewicz, E. et al. Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS ONE 6, e17517 (2011).","journal-title":"PLoS ONE"},{"key":"359_CR102","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.onc.1210791","volume":"27","author":"N Hafner","year":"2008","unstructured":"Hafner, N. et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27, 1610\u20131617 (2008).","journal-title":"Oncogene"},{"key":"359_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-009-0412-8","volume":"40","author":"R Ghittoni","year":"2010","unstructured":"Ghittoni, R. et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40, 1\u201313 (2010).","journal-title":"Virus Genes"},{"key":"359_CR104","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","volume":"26","author":"K Hoppe-Seyler","year":"2018","unstructured":"Hoppe-Seyler, K., Bossler, F., Braun, J. A., Herrmann, A. L. & Hoppe-Seyler, F. The HPV E6\/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 26, 158\u2013168 (2018).","journal-title":"Trends Microbiol."},{"key":"359_CR105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature16481","volume":"529","author":"D Martinez-Zapien","year":"2016","unstructured":"Martinez-Zapien, D. et al. Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53. Nature 529, 541\u2013545 (2016).","journal-title":"Nature"},{"key":"359_CR106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","volume":"5","author":"A Chabeda","year":"2018","unstructured":"Chabeda, A. et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 5, 46\u201358 (2018).","journal-title":"Papillomavirus Res."},{"key":"359_CR107","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14712598.8.4.421","volume":"8","author":"CF Hung","year":"2008","unstructured":"Hung, C. F., Ma, B., Monie, A., Tsen, S. W. & Wu, T. C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther. 8, 421\u2013439 (2008).","journal-title":"Expert Opin. Biol. Ther."},{"key":"359_CR108","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02426892 (2020)."},{"key":"359_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02858310 (2020)."},{"key":"359_CR110","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03418480 (2020)."},{"key":"359_CR111","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2017.00689","volume":"8","author":"Y Qin","year":"2017","unstructured":"Qin, Y. et al. Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front. Immunol. 8, 689 (2017).","journal-title":"Front. Immunol."},{"key":"359_CR112","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/pmic.201600140","volume":"16","author":"D Kumar","year":"2016","unstructured":"Kumar, D. et al. Integrating transcriptome and proteome profiling: strategies and applications. Proteomics 16, 2533\u20132544 (2016).","journal-title":"Proteomics"},{"key":"359_CR113","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bib\/bbw114","volume":"19","author":"C Manzoni","year":"2018","unstructured":"Manzoni, C. et al. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Brief. Bioinform. 19, 286\u2013302 (2018).","journal-title":"Brief. Bioinform."},{"key":"359_CR114","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-015-0082-4","volume":"7","author":"H Kuasne","year":"2015","unstructured":"Kuasne, H. et al. Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. Clin. Epigenetics 7, 46 (2015).","journal-title":"Clin. Epigenetics"},{"key":"359_CR115","doi-asserted-by":"crossref","first-page":"845340","DOI":"10.1155\/2015\/845340","volume":"2015","author":"E Frohlich","year":"2015","unstructured":"Frohlich, E. & Wahl, R. Chemotherapy and chemoprevention by thiazolidinediones. Biomed. Res. Int. 2015, 845340 (2015).","journal-title":"Biomed. Res. Int."},{"key":"359_CR116","doi-asserted-by":"crossref","first-page":"15294","DOI":"10.18632\/oncotarget.14783","volume":"8","author":"H Kuasne","year":"2017","unstructured":"Kuasne, H. et al. Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. Oncotarget 8, 15294\u201315306 (2017).","journal-title":"Oncotarget"},{"key":"359_CR117","doi-asserted-by":"crossref","first-page":"10990","DOI":"10.1073\/pnas.180329197","volume":"97","author":"E Mueller","year":"2000","unstructured":"Mueller, E. et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl Acad. Sci. USA 97, 10990\u201310995 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"359_CR118","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","volume":"18","author":"NN Khodarev","year":"2012","unstructured":"Khodarev, N. N., Roizman, B. & Weichselbaum, R. R. Molecular pathways: interferon\/STAT1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18, 3015\u20133021 (2012).","journal-title":"Clin. Cancer Res."},{"key":"359_CR119","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"359_CR120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","volume":"11","author":"T Fetter","year":"2020","unstructured":"Fetter, T. et al. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front. Immunol. 11, 344 (2020).","journal-title":"Front. Immunol."},{"key":"359_CR121","first-page":"91","volume":"35","author":"S Saeed","year":"2005","unstructured":"Saeed, S., Keehn, C. A., Khalil, F. K. & Morgan, M. B. Immunohistochemical expression of Bax and Bcl-2 in penile carcinoma. Ann. Clin. Lab. Sci. 35, 91\u201396 (2005).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"359_CR122","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.0022-202X.2004.22501.x","volume":"122","author":"VL Brown","year":"2004","unstructured":"Brown, V. L. et al. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J. Invest. Dermatol. 122, 1284\u20131292 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"359_CR123","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.3390\/ijms140610791","volume":"14","author":"H Kuasne","year":"2013","unstructured":"Kuasne, H., Marchi, F. A., Rogatto, S. R. & de Syllos Colus, I. M. Epigenetic mechanisms in penile carcinoma. Int. J. Mol. Sci. 14, 10791\u201310808 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"359_CR124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/path.1394","volume":"201","author":"E Ferreux","year":"2003","unstructured":"Ferreux, E. et al. Evidence for at least three alternative mechanisms targeting the p16INK4A\/cyclin D\/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J. Pathol. 201, 109\u2013118 (2003).","journal-title":"J. Pathol."},{"key":"359_CR125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1827.2008.02259.x","volume":"58","author":"N Yanagawa","year":"2008","unstructured":"Yanagawa, N., Osakabe, M., Hayashi, M., Tamura, G. & Motoyama, T. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in Japanese men. Pathol. Int. 58, 477\u2013482 (2008).","journal-title":"Pathol. Int."},{"key":"359_CR126","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00428-010-1007-4","volume":"458","author":"M Poetsch","year":"2011","unstructured":"Poetsch, M. et al. Alterations in the tumor suppressor gene p16INK4A are associated with aggressive behavior of penile carcinomas. Virchows Arch. 458, 221\u2013229 (2011).","journal-title":"Virchows Arch."},{"key":"359_CR127","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","volume":"435","author":"J Lu","year":"2005","unstructured":"Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834\u2013838 (2005).","journal-title":"Nature"},{"key":"359_CR128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nmeth717","volume":"1","author":"PT Nelson","year":"2004","unstructured":"Nelson, P. T. et al. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat. Methods 1, 155\u2013161 (2004).","journal-title":"Nat. Methods"},{"key":"359_CR129","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. MicroRNA expression profile in penile cancer revealed by next-generation small RNA sequencing. PLoS ONE 10, e0131336 (2015).","journal-title":"PLoS ONE"},{"key":"359_CR130","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ajpath.2014.08.004","volume":"184","author":"L Barzon","year":"2014","unstructured":"Barzon, L. et al. Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. Am. J. Pathol. 184, 3376\u20133383 (2014).","journal-title":"Am. J. Pathol."},{"key":"359_CR131","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00428-018-2404-3","volume":"473","author":"H Kuasne","year":"2018","unstructured":"Kuasne, H. et al. Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor. Virchows Arch. 473, 607\u2013614 (2018).","journal-title":"Virchows Arch."},{"key":"359_CR132","volume":"5","author":"XJ Li","year":"2014","unstructured":"Li, X. J., Ren, Z. J. & Tang, J. H. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 5, e1327 (2014).","journal-title":"Cell Death Dis."},{"key":"359_CR133","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0b013e3181a418ae","volume":"33","author":"A Chaux","year":"2009","unstructured":"Chaux, A. et al. Comparison of morphologic features and outcome of resected recurrent and nonrecurrent squamous cell carcinoma of the penis: a study of 81 cases. Am. J. Surg. Pathol. 33, 1299\u20131306 (2009).","journal-title":"Am. J. Surg. Pathol."},{"key":"359_CR134","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0022-5347(06)00313-2","volume":"175","author":"MW Kattan","year":"2006","unstructured":"Kattan, M. W. et al. Nomogram predictive of cancer specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. J. Urol. 175, 2103\u20132108 (2006).","journal-title":"J. Urol."},{"key":"359_CR135","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1074\/mcp.RA118.000935","volume":"17","author":"P Grabowski","year":"2018","unstructured":"Grabowski, P., Kustatscher, G. & Rappsilber, J. Epigenetic variability confounds transcriptome but not proteome profiling for coexpression-based gene function prediction. Mol. Cell Proteom. 17, 2082\u20132090 (2018).","journal-title":"Mol. Cell Proteom."},{"key":"359_CR136","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1994.355","volume":"70","author":"B Dix","year":"1994","unstructured":"Dix, B., Robbins, P., Carrello, S., House, A. & Iacopetta, B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer 70, 585\u2013590 (1994).","journal-title":"Br. J. Cancer"},{"key":"359_CR137","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","volume":"10","author":"AR Li","year":"2008","unstructured":"Li, A. R. et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J. Mol. Diagn. 10, 242\u2013248 (2008).","journal-title":"J. Mol. Diagn."},{"key":"359_CR138","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-10-0129","volume":"16","author":"A Kitamura","year":"2010","unstructured":"Kitamura, A., Hosoda, W., Sasaki, E., Mitsudomi, T. & Yatabe, Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin. Cancer Res. 16, 3349\u20133355 (2010).","journal-title":"Clin. Cancer Res."},{"key":"359_CR139","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1309\/AJCPST1CTHZS3PSZ","volume":"133","author":"LM Sholl","year":"2010","unstructured":"Sholl, L. M. et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am. J. Clin. Pathol. 133, 922\u2013934 (2010).","journal-title":"Am. J. Clin. Pathol."},{"key":"359_CR140","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/bjc.2011.135","volume":"104","author":"J Lehmann-Che","year":"2011","unstructured":"Lehmann-Che, J. et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br. J. Cancer 104, 1739\u20131746 (2011).","journal-title":"Br. J. Cancer"},{"key":"359_CR141","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/annonc\/mdv508","volume":"27","author":"Y Kuboki","year":"2016","unstructured":"Kuboki, Y. et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann. Oncol. 27, 127\u2013133 (2016).","journal-title":"Ann. Oncol."},{"key":"359_CR142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(05)64836-7","volume":"168","author":"A Lopes","year":"2002","unstructured":"Lopes, A. et al. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J. Urol. 168, 81\u201386 (2002).","journal-title":"J. Urol."},{"key":"359_CR143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-5347(05)65389-X","volume":"167","author":"AC Martins","year":"2002","unstructured":"Martins, A. C., Faria, S. M., Cologna, A. J., Suaid, H. J. & Tucci, S. Jr. Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J. Urol. 167, 89\u201392 (2002).","journal-title":"J. Urol."},{"key":"359_CR144","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clgc.2015.12.019","volume":"14","author":"K Zargar-Shoshtari","year":"2016","unstructured":"Zargar-Shoshtari, K. et al. Clinical significance of p53 and p16INK4A status in a contemporary North American penile carcinoma cohort. Clin. Genitourin. Cancer 14, 346\u2013351 (2016).","journal-title":"Clin. Genitourin. Cancer"},{"key":"359_CR145","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00345-013-1024-4","volume":"31","author":"JY Liu","year":"2013","unstructured":"Liu, J. Y. et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J. Urol. 31, 1519\u20131524 (2013).","journal-title":"World J. Urol."},{"key":"359_CR146","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.urolonc.2017.10.010","volume":"36","author":"K Zargar-Shoshtari","year":"2018","unstructured":"Zargar-Shoshtari, K., Sharma, P. & Spiess, P. E. Insight into novel biomarkers in penile cancer: redefining the present and future treatment paradigm? Urol. Oncol. 36, 433\u2013439 (2018).","journal-title":"Urol. Oncol."},{"key":"359_CR147","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1464-410X.2003.04315.x","volume":"92","author":"ME Laniado","year":"2003","unstructured":"Laniado, M. E., Lowdell, C., Mitchell, H. & Christmas, T. J. Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. BJU Int. 92, 248\u2013250 (2003).","journal-title":"BJU Int."},{"key":"359_CR148","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1464-410X.2007.06908.x","volume":"100","author":"Y Zhu","year":"2007","unstructured":"Zhu, Y., Zhou, X. Y., Yao, X. D., Dai, B. & Ye, D. W. The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery. BJU Int. 100, 204\u2013208 (2007).","journal-title":"BJU Int."},{"key":"359_CR149","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-223","volume":"13","author":"S Steffens","year":"2013","unstructured":"Steffens, S. et al. High CRP values predict poor survival in patients with penile cancer. BMC Cancer 13, 223 (2013).","journal-title":"BMC Cancer"},{"key":"359_CR150","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"359_CR151","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-319-93339-9_11","volume":"175","author":"K Attalla","year":"2018","unstructured":"Attalla, K., Sfakianos, J. P. & Galsky, M. D. Current role of checkpoint inhibitors in urologic cancers. Cancer Treat. Res. 175, 241\u2013258 (2018).","journal-title":"Cancer Treat. Res."},{"key":"359_CR152","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","volume":"197","author":"SR Ottenhof","year":"2017","unstructured":"Ottenhof, S. R. et al. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J. Urol. 197, 690\u2013697 (2017).","journal-title":"J. Urol."},{"key":"359_CR153","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager, A. M. et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann. Oncol. 27, 1706\u20131712 (2016).","journal-title":"Ann. Oncol."},{"key":"359_CR154","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","volume":"59","author":"M Cocks","year":"2017","unstructured":"Cocks, M. et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum. Pathol. 59, 55\u201361 (2017).","journal-title":"Hum. Pathol."},{"key":"359_CR155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13000-018-0689-9","volume":"13","author":"M Udall","year":"2018","unstructured":"Udall, M. et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn. Pathol. 13, 12 (2018).","journal-title":"Diagn. Pathol."},{"key":"359_CR156","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","volume":"9","author":"SR Ottenhof","year":"2018","unstructured":"Ottenhof, S. R. et al. The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma. Front. Immunol. 9, 1253 (2018).","journal-title":"Front. Immunol."},{"key":"359_CR157","doi-asserted-by":"crossref","first-page":"87244","DOI":"10.18632\/oncotarget.20244","volume":"8","author":"Z Cheng","year":"2017","unstructured":"Cheng, Z., Zhang, D., Gong, B., Wang, P. & Liu, F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget 8, 87244\u201387262 (2017).","journal-title":"Oncotarget"},{"key":"359_CR158","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00432-018-2646-0","volume":"144","author":"S Garvin","year":"2018","unstructured":"Garvin, S., Oda, H., Arnesson, L. G., Lindstrom, A. & Shabo, I. Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. J. Cancer Res. Clin. Oncol. 144, 1253\u20131263 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"359_CR159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jlb.67.1.97","volume":"67","author":"C Buechler","year":"2000","unstructured":"Buechler, C. et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J. Leukoc. Biol. 67, 97\u2013103 (2000).","journal-title":"J. Leukoc. Biol."},{"key":"359_CR160","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ijc.27506","volume":"131","author":"MB Maniecki","year":"2012","unstructured":"Maniecki, M. B. et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int. J. Cancer 131, 2320\u20132331 (2012).","journal-title":"Int. J. Cancer"},{"key":"359_CR161","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39\u201351 (2010).","journal-title":"Cell"},{"key":"359_CR162","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"Gooden, M. J., de Bock, G. H., Leffers, N., Daemen, T. & Nijman, H. W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105, 93\u2013103 (2011).","journal-title":"Br. J. Cancer"},{"key":"359_CR163","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni, E. et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl Acad. Sci. USA 115, E4041\u2013E4050 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"359_CR164","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/2326-6066.CIR-16-0400","volume":"5","author":"M Hennequart","year":"2017","unstructured":"Hennequart, M. et al. Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol. Res. 5, 695\u2013709 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"359_CR165","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-1032-3","volume":"10","author":"D Golijanin","year":"2004","unstructured":"Golijanin, D. et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res. 10, 1024\u20131031 (2004).","journal-title":"Clin. Cancer Res."},{"key":"359_CR166","volume":"143","author":"M Surace","year":"2019","unstructured":"Surace, M. et al. Automated multiplex immunofluorescence panel for immuno-oncology studies on formalin-fixed carcinoma tissue specimens. J. Vis. Exp. 143, e58390 (2019).","journal-title":"J. Vis. Exp."},{"key":"359_CR167","volume":"2","author":"Z Feng","year":"2017","unstructured":"Feng, Z. et al. Multiparametric immune profiling in HPV-oral squamous cell cancer. JCI Insight 2, e93652 (2017).","journal-title":"JCI Insight"},{"key":"359_CR168","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"359_CR169","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coi.2017.01.005","volume":"45","author":"D Bethmann","year":"2017","unstructured":"Bethmann, D., Feng, Z. & Fox, B. A. Immunoprofiling as a predictor of patient\u2019s response to cancer therapy \u2014 promises and challenges. Curr. Opin. Immunol. 45, 60\u201372 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"359_CR170","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"359_CR171","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"359_CR172","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","volume":"26","author":"L Chang","year":"2018","unstructured":"Chang, L., Chang, M., Chang, H. M. & Chang, F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl. Immunohistochem. Mol. Morphol. 26, e15\u2013e21 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"359_CR173","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00018-018-2906-9","volume":"75","author":"M Ratti","year":"2018","unstructured":"Ratti, M., Lampis, A., Hahne, J. C., Passalacqua, R. & Valeri, N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol. Life Sci. 75, 4151\u20134162 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"359_CR174","first-page":"11","volume":"38","author":"DT Le","year":"2020","unstructured":"Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11\u201319 (2020).","journal-title":"J. Clin. Oncol."},{"key":"359_CR175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43\u201351 (2015).","journal-title":"Cancer Discov."},{"key":"359_CR176","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat, S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin. Cancer Res. 23, 1920\u20131928 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl.5","key":"359_CR177","first-page":"v403","volume":"28","author":"AK Singavi","year":"2017","unstructured":"Singavi, A. K. et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI): analysis of somatic alterations (SAs). Ann. Oncol. 28(Suppl.5), v403\u2013v427 (2017).","journal-title":"Ann. Oncol."},{"key":"359_CR178","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato, S. et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res. 23, 4242\u20134250 (2017).","journal-title":"Clin. Cancer Res."},{"key":"359_CR179","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83\u201396 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"359_CR180","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76, 999\u20131008 (2016).","journal-title":"Cancer Res."},{"key":"359_CR181","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."},{"key":"359_CR182","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden, M. R. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 379, 341\u2013351 (2018).","journal-title":"N. Engl. J. Med."},{"key":"359_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03391479 (2019)."},{"key":"359_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03686332 (2019)."},{"key":"359_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02834013 (2020)."},{"key":"359_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02496208 (2020)."},{"key":"359_CR187","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728\u2013732 (2017).","journal-title":"Nature"},{"key":"359_CR188","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3322\/caac.21398","volume":"67","author":"AP Bhatt","year":"2017","unstructured":"Bhatt, A. P., Redinbo, M. R. & Bultman, S. J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin. 67, 326\u2013344 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"359_CR189","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ebiom.2015.04.010","volume":"2","author":"JJ Goedert","year":"2015","unstructured":"Goedert, J. J. et al. Fecal microbiota characteristics of patients with colorectal adenoma detected by screening: a population-based study. EBioMedicine 2, 597\u2013603 (2015).","journal-title":"EBioMedicine"},{"key":"359_CR190","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1128\/AEM.01235-16","volume":"82","author":"C Urbaniak","year":"2016","unstructured":"Urbaniak, C. et al. The microbiota of breast tissue and its association with breast cancer. Appl. Env. Microbiol. 82, 5039\u20135048 (2016).","journal-title":"Appl. Env. Microbiol."},{"key":"359_CR191","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-020-00811-2","volume":"8","author":"Y Heshiki","year":"2020","unstructured":"Heshiki, Y. et al. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome 8, 28 (2020).","journal-title":"Microbiome"},{"key":"359_CR192","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"359_CR193","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1177\/0148607115584387","volume":"40","author":"ML Consoli","year":"2016","unstructured":"Consoli, M. L. et al. Randomized clinical trial: impact of oral administration of Saccharomyces boulardii on gene expression of intestinal cytokines in patients undergoing colon resection. J. Parenter. Enter. Nutr. 40, 1114\u20131121 (2016).","journal-title":"J. Parenter. Enter. Nutr."},{"key":"359_CR194","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41585-020-0286-z","volume":"17","author":"P Laniewski","year":"2020","unstructured":"Laniewski, P., Ilhan, Z. E. & Herbst-Kralovetz, M. M. The microbiome and gynaecological cancer development, prevention and therapy. Nat. Rev. Urol. 17, 232\u2013250 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"359_CR195","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/1471-0528.15854","volume":"127","author":"J Norenhag","year":"2020","unstructured":"Norenhag, J. et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG 127, 171\u2013180 (2020).","journal-title":"BJOG"},{"key":"359_CR196","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/ijgc-2018-000032","volume":"29","author":"XP Chao","year":"2019","unstructured":"Chao, X. P. et al. Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 29, 28\u201334 (2019).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"359_CR197","volume":"8","author":"CM Liu","year":"2017","unstructured":"Liu, C. M. et al. Penile anaerobic dysbiosis as a risk factor for HIV infection. MBio 8, e00996-17 (2017).","journal-title":"MBio"},{"key":"359_CR198","volume":"5","author":"LB Price","year":"2010","unstructured":"Price, L. B. et al. The effects of circumcision on the penis microbiome. PLoS ONE 5, e8422 (2010).","journal-title":"PLoS ONE"},{"key":"359_CR199","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","volume":"33","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A. & Wargo, J. A. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33, 570\u2013580 (2018).","journal-title":"Cancer Cell"},{"key":"359_CR200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12866-020-01759-x","volume":"20","author":"H Onywera","year":"2020","unstructured":"Onywera, H. et al. The penile microbiota of black South African men: relationship with human papillomavirus and HIV infection. BMC Microbiol. 20, 78 (2020).","journal-title":"BMC Microbiol."},{"key":"359_CR201","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature11553","volume":"489","author":"GM Weinstock","year":"2012","unstructured":"Weinstock, G. M. Genomic approaches to studying the human microbiota. Nature 489, 250\u2013256 (2012).","journal-title":"Nature"},{"key":"359_CR202","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1101\/gr.096651.109","volume":"19","author":"NHW Group","year":"2009","unstructured":"Group, N. H. W. et al. The NIH human microbiome project. Genome Res. 19, 2317\u20132323 (2009).","journal-title":"Genome Res."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-0359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-0359-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-0359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T23:16:56Z","timestamp":1629242216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-0359-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":202,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1038\/s41585-020-0359-z","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"3 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.R.: employment: Foundation Medicine; leadership: Foundation Medicine; stock and other ownership interests: Foundation Medicine; research funding: Foundation Medicine. A.N.: employment: Bayer A.G.; stock and other ownership interests: Bayer A.G.; honoraria: Roche Merck, AstraZeneca, Janssen Pharmaceuticals, and Foundation Medicine; consulting or advisory role: Merck Sharp & Dohme, Roche, Bayer A.G., AstraZeneca, Clovis Oncology, Janssen Pharmaceuticals, Incyte, Seattle Genetics, Astellas Pharma, Bristol-Myers Squibb and Rainier Therapeutics; research funding: Merck Sharp & Dohme (to the institute) and AstraZeneca (to the institute); travel, accommodations, expenses: Roche, Merck Sharp & Dohme, AstraZeneca and Janssen Pharmaceuticals. P.E.S.: consulting or advisory role: Genentech and Pfizer. A.M.A., J.C., J.J.A., M.A. and A.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}